Drugs / BG1805
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06347458 | Apr 2024 → Apr 2027 expected | acute myeloid leukemia | Guangzhou Bio-gene Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06118788 | Mar 2024 → Mar 2027 expected | acute myeloid leukemia | Guangzhou Bio-gene Technology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG1805 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06347458 ↗ |
| Route | Intravenous | “administered intravenously” NCT06118788 ↗ |